A novel fibroblast activation inhibitor attenuates left ventricular remodeling and preserves cardiac function in heart failure
Cardiac fibroblasts are critical mediators of fibrotic remodeling in the failing heart and transform into ...
October 20, 2020
Novel Dual MTOR Inhibitor/AMPK Activator Mitigates Doxorubicin Cardiotoxicity And Potentiates Its Chemotherapeutic Efficacy Against Triple Negative Breast Cancer”, Scientific Sessions 2020
April 26, 2020
Synergistic anti-metastatic effect of pembrolizumab in combination with a novel mTORC1 inhibitor/AMPK agonist in a CAM metastatic triple negative breast cancer model, Virtual AACR 2020 Annual Meeting
“Novel Dual MTOR Inhibitors/AMPK Activators Attenuate Doxorubicin-induced Cardiotoxicity” Rapid Fire Oral Presentation in American Heart Association Scientific Sessions
A novel fibroblast activation inhibitor attenuates left ventricular remodeling and preserves cardiac function in heart failure, American Journal of Physiology Heart and Circulatory Physiology